Form 4: CRL CEO Acquires Shares, Updates Holdings

Charles River Laboratories CEO James C. Foster acquired 16,796 shares of common stock and updated his beneficial ownership.

Summary

• James C. Foster, Chairman, President, and CEO of Charles River Laboratories International, Inc. (CRL), reported changes in his beneficial ownership.
• Acquired 16,796 shares of Common Stock at a price of $178.61 per share, which are unvested restricted stock units.
• These acquired restricted stock units are scheduled to vest on March 2, 2028.
• An exempt transfer of 9,220 shares occurred from the 2025 GRAT account to direct holdings, pursuant to Rule 16a-13.
• The transaction was made pursuant to a Rule 10b5-1(c) plan.
• Following these transactions, Foster directly owns 279,693 shares of Common Stock.
• Indirect holdings include 5,423 shares in 2024 GRAT, 10,780 shares in 2025 GRAT, 3,230 shares across various trusts, and 10,000 shares held by his spouse.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a CEO's acquisition of shares, even if part of a compensation plan, generally reflects confidence in the company's future performance.

Positives

• The acquisition of 16,796 shares by the CEO, even as restricted stock units, demonstrates continued alignment of management's interests with shareholders.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned, non-discretionary acquisition.

Future Outlook

The filing indicates the vesting of 16,796 restricted stock units on March 2, 2028, aligning executive compensation with future company performance.

Industry Context

StockSavvy.ai notes that insider acquisitions, particularly by top executives like the CEO, are often viewed positively by the market as they signal management's belief in the company's long-term prospects, especially in the life sciences and research services sector where Charles River Laboratories operates.

Comparison to Industry Standards

• StockSavvy.ai observes that executive stock acquisitions are a common practice across industries, including the pharmaceutical and biotechnology services sector.
• While specific comparisons to other CEOs' acquisition sizes would require detailed analysis of their compensation structures and company market caps (e.g., comparing to executives at LabCorp or Catalent), the acquisition of restricted stock units is a standard component of executive incentive plans designed to align interests with shareholders.

Stakeholder Impact

• Shareholders: May view the CEO's acquisition of shares as a positive indicator of management confidence, potentially bolstering investor sentiment.

Next Steps

• Vesting of 16,796 restricted stock units on March 2, 2028.

Key Dates

Recommendation

The CEO's acquisition of restricted stock units is a standard component of executive compensation and reflects an alignment of interests with shareholders. While not a discretionary open-market purchase, it indicates continued commitment. The transfer of shares from a GRAT to direct holdings is an internal reclassification and does not signal a change in investment thesis. Therefore, maintaining a 'hold' recommendation is appropriate based solely on this filing, awaiting further operational or financial updates.

Keywords

Charles River Laboratories, CRL, James C. Foster, Insider Trading, Form 4, Stock Acquisition, Restricted Stock Units, CEO, Beneficial Ownership